Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2015 May 6;14(7):1680–1692. doi: 10.1158/1535-7163.MCT-15-0080

Figure 4.

Figure 4

Vemurafenib induces significant loss of HKII in both sensitive and intrinsically resistant lines. A, 3μM Vemurafenib induces a decrease in overall hexokinase activity per cell after 72 hours in sensitive cell lines B, Vemurafenib (+) induces near complete loss of HKII in sensitive but not C, acquired resistant or non-BRAF cell lines at 72 hours relative to DMSO (−). D, Intrinsically resistant cell lines show a decrease in HKII comparable to sensitive cell lines. E, Sensitive and intrinsically resistant lines show a significant increase in HKI with Vemurafenib treatment by 72 hours that is not observed in acquired resistant or non-BRAF mutant lines, F.